July 2, 2026
10:18 pm

How Life Settlement Pricing Has Changed Since 2010

Life settlement pricing since 2010 has been shaped by four forces: the conservative repricing that followed the late-2000s life expectancy revisions, a decade of historically low interest rates that supported policy values, a wave of carrier cost-of-insurance increases that repriced the cost of holding policies, and steadily better underwriting data that tied offers more tightly to individual health. The valuation method itself never changed — buyers still discount a policy’s expected death benefit and premiums to present value — but every major input into that calculation has moved over fifteen years. The GAO’s benchmark range of roughly 10–35% of face value has endured, while where a given policy lands within it has become a more precise, more evidence-driven question.

This article traces the pricing story era by era — from the post-crisis reset through the low-rate decade to the higher-rate 2020s — and what the changes mean for a policyholder evaluating an offer today.

In This Article

The Constant: How Life Settlements Have Always Been Priced
2010–2012: Pricing in the Shadow of the LE Revisions
2012–2020: The Low-Rate Decade Rebuilds the Bid
The Cost-of-Insurance Shock: Carriers Reprice the Carry
The Underwriting Revolution: Data Sharpens the Price
The 2020s: Higher Rates Reset the Equation Again
What Fifteen Years of Pricing Change Means for Sellers Today
Frequently Asked Questions

How Life Settlement Pricing Has Changed Since 2010

The Constant: How Life Settlements Have Always Been Priced

Before tracing what changed, fix what did not. A life settlement is priced, in 2010 as now, by discounted cash flow. The buyer projects two streams: the premiums required to keep the policy in force for the insured’s remaining lifetime, and the death benefit expected at maturity. The timing rests on life expectancy (LE) estimates from independent medical underwriters; the streams are netted and discounted to present value at the investor’s required rate of return; and the resulting value, minus transaction costs and margins, bounds the offer a seller can receive. The full machinery is described in life settlement pricing mechanics.

That framework makes pricing changes easy to organize, because only four inputs can move:

Life expectancy estimates — how long underwriters project insureds will live, and with what confidence.
Premium projections — what it costs to carry the policy, set by carrier charges and policy design.
Discount rates — the return investors demand, shaped by interest rates, competition, and perceived risk.
Transaction structure — intermediation costs and competitive dynamics between gross and net offers.

Every era since 2010 is a story about which of these inputs moved and why. The benchmark documented by the U.S. Government Accountability Office in GAO-10-775 — settlements typically paying 10–35% of face value, often four to eight times cash surrender value — has proven remarkably durable as a range precisely because the inputs have often moved in offsetting directions.

2010–2012: Pricing in the Shadow of the LE Revisions

The market that entered 2010 was still absorbing its formative shock. In the late 2000s, the major life expectancy underwriting firms had lengthened their estimates substantially after incorporating better mortality data on insured seniors — and portfolios priced on the older, shorter estimates were impaired across the industry. Simultaneously, the financial crisis had drained risk capital from every alternative asset class, and the STOLI scandals had cast legal doubt over swaths of policies originated in the mid-2000s.

The pricing consequences defined the era:

Higher discount rates. The investors who remained demanded substantially higher returns to compensate for demonstrated LE uncertainty, legal risk on origination, and scarce capital — and higher discount rates translate directly into lower offers.
Conservative LE treatment. Buyers began systematically requiring two independent LE reports, reconciling divergence toward the longer estimate, and adding in-house conservatism on top.
Origination scrutiny. Policies with premium-financing fingerprints or insurable-interest questions were discounted heavily or rejected outright, as buyers priced the risk that a STOLI-tainted policy could be challenged years later.
A thinner, choosier market. Marginal policies that might have traded in 2007 found no bids.

For sellers, this was the cycle’s trough: fewer buyers, tougher underwriting, lower prices. It was also the foundation of the modern market’s discipline — the conservatism installed in these years never fully left, as the fuller narrative in our history of life settlements recounts.

2012–2020: The Low-Rate Decade Rebuilds the Bid

As the 2010s progressed, the single most powerful pricing force became the interest-rate environment. With central banks holding rates near historic lows for most of the decade, institutional investors everywhere faced the same problem: traditional fixed income yielded little, and capital went hunting for return. Life settlements — offering equity-like target returns driven by mortality rather than markets — fit the moment, and capital flowed back into the asset class through funds, managed accounts, and tertiary portfolio purchases.

The pricing effects compounded through the decade:

Discount-rate compression. As more capital competed for a limited supply of quality policies, the returns investors could demand declined from the distressed levels of 2010–2012. Lower discount rates mean higher present values — and better offers to sellers. The mechanics of this relationship are detailed in discount rates in life settlement pricing.
A liquid tertiary market. Funds trading whole portfolios among themselves improved price discovery and gave primary buyers confidence they could exit, further supporting bids.
Broadened eligibility. Competition pushed buyers up the health spectrum: policies on longer-LE insureds that would have found no market in 2010 began attracting offers, and smaller face amounts became transactable.
Stabilized LE methodology. Underwriters published actual-to-expected studies, revisions became incremental rather than seismic, and pricing confidence improved accordingly.

By the late 2010s, the seller’s market had visibly improved from the post-crisis trough — competition, not generosity, doing the work.

Era	Dominant Force	Effect on Discount Rates	Effect on Seller Offers
2010–2012	Post-crisis capital scarcity; LE-revision aftermath; STOLI legal risk	Elevated	Cycle trough: fewer buyers, conservative pricing
2012–2015	Low rates draw capital back; underwriting stabilizes	Beginning to compress	Gradual recovery in bids
2015–2018	Carrier cost-of-insurance increases; competition builds	Compressing, with new COI risk premium	Better offers overall; carrier exposure repriced
2018–2021	Mature institutional market; tertiary liquidity; data-driven underwriting	Near-cycle lows	Broadest eligibility; strongest competition
2022–2025	Rapid rate rises; supply growth from boomers and carrying costs	Rising again	Marginal policies reprice; quality policies stay contested

2012–2020: The Low-Rate Decade Rebuilds the Bid

The Cost-of-Insurance Shock: Carriers Reprice the Carry

Mid-decade, a force outside the settlement market itself reshaped pricing: life insurance carriers began raising cost-of-insurance (COI) charges on blocks of in-force universal life policies. Carriers attributed the increases to the same low-rate environment buoying asset prices — policies designed in higher-rate eras were earning less on their reserves than assumed — and some blocks saw substantial premium impacts. Litigation between policyholders (including institutional owners of settled policies) and carriers followed, with a series of disputes and settlements playing out over subsequent years.

For settlement pricing, COI risk changed the arithmetic in three ways:

Higher projected premiums on affected policies. Since the premium stream is half of the valuation, COI increases directly reduced what buyers could pay for exposed policies.
A new risk premium. Even unaffected policies now carried the possibility of future increases, and buyers began stress-testing premium projections and discounting carriers with a history of aggressive repricing. Carrier identity became a pricing variable in a way it had not been before.
More sellers. Ironically, COI increases also drove supply: policyholders facing suddenly unaffordable premiums were exactly the owners who explored selling rather than lapsing.

The episode taught both sides a durable lesson. Buyers learned that premium projections are promises only as good as carrier behavior; sellers learned that the cost of keeping a policy can change after decades of ownership. Policy-specific premium structure — guarantees, no-lapse riders, funding levels — became a larger determinant of price, a topic developed in how life settlement investors make money.

The Underwriting Revolution: Data Sharpens the Price

Running beneath the rate and COI stories was a quieter transformation in how insureds are evaluated — and it changed not the average price so much as the precision of every price.

In 2010, LE underwriting was already professionalizing after its crisis, but the raw material remained paper medical records reviewed manually. Over the following fifteen years, the inputs got richer: electronic health records, prescription-history databases, lab-value data, and clinical scoring systems entered the workflow, and underwriters refreshed their mortality assumptions as actuarial bodies updated the underlying tables — the machinery described in life expectancy tables used in life settlements.

The pricing consequences for sellers are concrete:

Tighter linkage between health and offer. Well-documented impairments are credited more fully and confidently, so two insureds of the same age with different health profiles see appropriately different prices rather than a blended, cautious average.
Documentation as money. Complete, current medical records reduce the uncertainty buyers must price against; gaps get resolved conservatively — toward longer LE and lower offers.
Faster evaluation. Data-driven underwriting compressed parts of the process, though full transactions still generally run 60–120 days through escrowed closing.
Fewer mispricings in both directions. The wild bargains and wild overpayments of the early market — artifacts of crude estimation — became rarer as the error bars narrowed around each independent life expectancy report.

The net effect: pricing since 2010 has become less about the market’s mood and more about the individual policy’s evidence.

The 2020s: Higher Rates Reset the Equation Again

The rapid rate increases of the early-to-mid 2020s ended the environment that had defined settlement pricing for a decade — and reintroduced a tension the market had not felt since before the low-rate era.

On the valuation side, higher prevailing rates pushed investors’ required returns upward. When safe assets yield meaningfully again, an illiquid, longevity-exposed asset must offer more to compete, and higher discount rates mechanically reduce the present value of far-off death benefits. All else equal, that pressure works against sellers, partially unwinding the discount-rate compression of the 2010s.

But all else was not equal, and offsetting forces cushioned the reset:

Supply pressure intensified. Higher carrying costs, COI legacy effects, and inflation squeezing retiree budgets pushed more policyholders to evaluate selling — and the demographic wave of boomers crossing settlement age kept building, as described in the baby boomer life settlement wave.
Capital stayed institutional and committed. Unlike 2008, the higher-rate transition produced no exodus; the investor base built over the 2010s — pensions, asset managers, ILS funds — treats the allocation as strategic.
Competition for quality persisted. Well-documented policies on impaired insureds continued to attract multiple bids, keeping realized prices for the strongest cases resilient even as marginal policies repriced.

The relationship between rates and this market — in both directions — is examined in interest rates and the secondary market. The 2020s lesson echoes the whole period since 2010: the pricing framework is stable; the inputs are not.

What Fifteen Years of Pricing Change Means for Sellers Today

Distilled, the post-2010 pricing story leaves a seller with five practical takeaways.

The range endures; your position within it is personal. The GAO’s 10–35%-of-face benchmark has survived every era because offsetting forces kept it relevant. What changed is precision: your offer now reflects your specific health documentation, your policy’s premium structure, your carrier’s behavior, and current investor return requirements — not a market-wide rule of thumb.

Documentation is leverage. The underwriting revolution rewards complete, current medical records. Assembling them before shopping a policy is the cheapest price improvement available.

Premium structure matters more than ever. Post-COI-era buyers scrutinize carrying costs; a policy with guarantees or efficient funding prices better than an exposed one with identical face value.

Competition remains the seller’s engine. Every era since 2012 confirms that multiple bids — through a licensed broker with a duty to the seller, or direct solicitation of several licensed providers — is what moves an offer from the bottom of the achievable range toward the top.

The protections are constant even as prices move. Licensing, disclosure, escrow, and rescission windows of 15–30 days depending on the state apply in every rate environment, under statutes modeled on the NAIC framework. Pricing eras come and go; the decision discipline — verify licenses, compare against surrender and alternatives, take independent tax advice, and start from what a life settlement is — does not.

Frequently Asked Questions

Are life settlement payouts higher or lower today than in 2010?

For most qualifying policies, the market of today is more competitive than the post-crisis market of 2010–2012, which was the modern cycle’s trough — capital had fled, life expectancy estimates had just lengthened, and the remaining buyers demanded high returns. The 2010s rebuilt competition and compressed discount rates, improving offers; the higher-rate 2020s partially reversed that for marginal policies while quality policies remained contested. The GAO’s typical range of 10–35% of face value has framed the whole period.

Why did life settlement offers drop after the late-2000s life expectancy revisions?

Because the market’s central input moved against buyers all at once. Major life expectancy underwriters lengthened their estimates after incorporating better mortality data on insured seniors, meaning portfolios purchased on shorter estimates were suddenly worth less — more premium years, later death benefits. Burned investors responded by demanding higher returns, requiring multiple independent LE reports, and pricing conservatively. Higher required returns and longer assumed lifespans both translate directly into lower offers, defining the 2010–2012 pricing trough.

How did the low interest rates of the 2010s affect life settlement prices?

Low rates were the decade’s biggest tailwind for sellers. With traditional fixed income yielding very little, institutional capital sought returns in alternatives, and life settlements’ mortality-driven, market-independent profile attracted funds, pensions, and ILS investors. As more capital competed for a limited supply of quality policies, the returns investors could demand compressed — and lower discount rates mean higher present values and better offers. Competition also broadened eligibility to healthier insureds and smaller policies that earlier markets ignored.

What were the cost-of-insurance increases and how did they change pricing?

In the mid-2010s, several carriers raised cost-of-insurance charges on blocks of in-force universal life policies, citing prolonged low rates relative to the assumptions those products were built on. For settlement pricing, higher COI meant higher projected premiums — directly reducing what buyers could pay for affected policies — and introduced a lasting risk premium, since any policy might face future increases. Carrier identity and premium-guarantee structure became explicit pricing variables, and the increases also pushed more squeezed policyholders to consider selling.

Do rising interest rates in the 2020s mean I should have sold my policy earlier?

Not necessarily. Higher rates did push investor return requirements up, which pressures valuations — but offsetting forces cushioned the market: growing policy supply, sustained institutional capital, and continued competition for well-documented policies on impaired insureds. More importantly, individual factors dominate timing: health changes, premium escalation, and how the policy is shopped move an offer far more than the rate cycle does. A policy evaluated today with complete records and multiple bids can still price well within the historical range.

Has the method for valuing life settlements changed since 2010?

The method is unchanged: buyers project the premiums needed to maintain the policy and the death benefit expected at maturity, then discount the net cash flows to present value using life expectancy estimates and a required rate of return. What changed are the inputs — LE methodology stabilized and became data-driven, premium projections now price carrier cost-of-insurance risk, and discount rates traveled from post-crisis highs through a decade of compression and back up with 2020s rates.

Why do two similar policies get very different life settlement offers today?

Because pricing has become far more individualized than it was in 2010. Modern underwriting ties the life expectancy estimate tightly to documented health conditions, so differences in medical evidence produce different LEs and different prices. Premium structure matters too: a policy with secondary guarantees or efficient funding costs less to carry than an exposed policy from a carrier with a history of cost-of-insurance increases. Finally, competition varies — a policy shopped to multiple licensed buyers typically prices better than one shown to a single provider.

What can I do to get the best price for my policy in the current market?

Three levers matter most. First, documentation: assemble complete, current medical records, since underwriting gaps are resolved conservatively against you. Second, competition: use a licensed broker who owes you a statutory duty, or solicit several licensed providers directly, so multiple bids discipline the price. Third, process: understand your policy’s premium structure and any guarantees, verify every license with your state insurance department, insist on independent escrow, and review the disclosures and your state’s 15–30 day rescission window with an independent adviser before signing.

Find out what your policy is worth — free, confidential, no obligation.

A 15-minute educational review covers your eligibility, every alternative, and a realistic view of what each path would net you.

Call (305) 209-7183 · Request a review online →

Table of Contents